Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

CMPX has been the subject of several other reports. Lifesci Capital initiated coverage on shares of Compass Therapeutics in a report on Monday, October 6th. They set an “outperform” rating and a $10.00 target price for the company. Leerink Partnrs upgraded shares of Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, October 6th. Citigroup assumed coverage on shares of Compass Therapeutics in a research report on Wednesday. They issued an “outperform” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Stock Up 1.1%

Shares of CMPX stock opened at $5.28 on Wednesday. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $5.86. The stock has a market cap of $939.10 million, a PE ratio of -11.73 and a beta of 1.44. The business has a 50-day simple moving average of $4.33 and a 200-day simple moving average of $3.37.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. Sell-side analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its holdings in shares of Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares in the last quarter. Creative Planning acquired a new position in Compass Therapeutics during the second quarter worth about $30,000. Strs Ohio purchased a new stake in Compass Therapeutics during the 1st quarter valued at about $34,000. Apollon Wealth Management LLC acquired a new stake in Compass Therapeutics in the 3rd quarter valued at about $35,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.